Patient Satisfaction

Allergic rhinitis patients reported high levels of satisfaction for ZETONNA® (ciclesonide) Nasal Aerosol14

Based on Regimen Attributes Composite satisfaction score


Regimen Attributes Composite score*†14

Methods14

A 2-week, randomized, multi-center, 2-period study in patients ≥ 12 years with PAR.

Randomized patients (N=327) received ZETONNA® (ciclesonide) Nasal Aerosol 74 mcg after a 2-week washout period.

Patient satisfaction with ZETONNA was evaluated after 2 weeks of treatment, expressed from the Regimen Attributes Composite subscale of the Allergic Rhinitis Treatment Satisfaction and Preference (ARTSP) instrument, a patient-reported outcomes measure.

The Regimen Attributes Composite score was a coprimary endpoint comprising the average of the sensory impact and regimen management subscales.

*On a scale of 0 to 100, where higher scores reflect higher satisfaction

**Baseline reflects recall of satisfaction with prior prescription nasal spray treatment taken within 6 months of trial entry.
 

The 76-item satisfaction scale on the ARTSP has 9 satisfaction subscales, 2 of which comprise the Regimen Attributes Composite Score14,‡

Regimen Attributes Composite
Sensory impact
Sensory attributes such as running out of the nose and running down the throat, taste, and smell related to the treatment
 
Regimen Management
Describes issues relating to dosing such as number of sprays and ease of use
 
Interference
How much allergy symptoms or side effects of the nasal spray interfere with one's daily routin
 
Regimen adaptation
Convenience and level of satisfaction with the current treatment
 
Role limitation
Interference with social interactions
 
Regimen difficulties
Levels of pain, discomfort, and side effects perceived to be associated with the treatment
 
Hassle
Amount of hassle experienced due to treatment regimen
 
Burden
Degree of burden associated with the treatment
 
Perceived relief
Level of relief and satisfaction with the treatment


‡After 2 weeks of treatment with ZETONNA, improvement from baseline in satisfaction scores was demonstrated in 8 of 9 ARTSP subscales.

Reference:
14. www.clinicaltrials.gov, NCT01401465. CSR 060-302. Sunovion Pharmaceuticals Inc., Marlborough, MA.

Stayability is a registered trademark of Sunovion Pharmaceuticals Inc.

 

Important Safety Information & Indication

In clinical studies local nasal effects of epistaxis, ulcerations, and nasal septal perforations were observed with ZETONNA® (ciclesonide) Nasal Aerosol. In the short-term and long term trials combined, nasal septal perforations were reported in 2 patients of 2335 treated with ZETONNA Nasal Aerosol compared with none of 892 treated with placebo. Both perforations occurred in 2 week SAR trials while none occurred in the longer term trials. In clinical trials with another formulation of ciclesonide, the development of localized infections of the nose or pharynx with Candida albicans has occurred. Corticosteroids can interfere with wound healing.

Prior to initiating therapy, examine patients for evidence of septal perforation, erosions, ulceration, nasal surgery, and trauma. Avoid spraying ZETONNA Nasal Aerosol directly onto the nasal septum. Avoid use in patients with recent septal perforation, nasal erosion, nasal ulcers, nasal surgery, or nasal trauma. Monitor patients periodically for signs of adverse reactions on the nasal mucosa. Discontinue ZETONNA Nasal Aerosol if erosions, ulcerations or perforations occur.

Nasal and inhaled corticosteroids may result in the development of glaucoma and cataracts. Monitor patients closely with a change in vision or with a history of increased intraocular pressure, glaucoma, or cataracts.

ZETONNA Nasal Aerosol is contraindicated in patients with a known hypersensitivity to ciclesonide or any of the ingredients of ZETONNA Nasal Aerosol. Cases of hypersensitivity reactions following administration of ciclesonide with manifestations such as angioedema, with swelling of the lips, tongue and pharynx have been reported.

Patients who are using immunosuppressant doses of corticosteroids are more susceptible to infections than healthy individuals. Chicken pox and measles can have a more serious or even fatal course in susceptible individuals. Inhaled corticosteroids should be used with caution, if at all, in patients with active or quiescent tuberculosis infections of the respiratory tract; untreated local or systemic fungal or bacterial infections, systemic viral or parasitic infections; or ocular herpes simplex because of the potential for worsening of these infections.

When intranasal corticosteroids are used at very high dosages or at the regular dosage in susceptible individuals, systemic corticosteroid effects such as hypercorticism and adrenal suppression may appear. If such changes occur, discontinue ZETONNA Nasal Aerosol slowly.

Corticosteroids may cause a reduction in growth velocity in children. Monitor growth routinely in pediatric patients receiving ZETONNA Nasal Aerosol.

In trials 2-6 weeks in duration, the most common adverse reactions that occurred with an incidence of at least 2% and more frequently with ZETONNA Nasal Aerosol than with placebo were nasal discomfort (3.2%), headache (3.1%) and epistaxis (2.9%).

For additional information, please see the ZETONNA Nasal Aerosol Full Prescribing Information.

Indication
ZETONNA® (ciclesonide) Nasal Aerosol is a corticosteroid indicated for the treatment of symptoms associated with seasonal and perennial allergic rhinitis in adults and adolescents 12 years of age and older.